Comparative Pharmacology
Head-to-head clinical analysis: MPI KRYPTON 81M GENERATOR versus SODIUM CHROMATE CR 51.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI KRYPTON 81M GENERATOR versus SODIUM CHROMATE CR 51.
MPI KRYPTON 81M GENERATOR vs SODIUM CHROMATE CR 51
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Krypton-81m (81mKr) is a short-lived radionuclide that decays by isomeric transition emitting gamma rays (190 keV). When inhaled, it distributes in the lungs according to regional ventilation. Imaging is performed using a gamma camera to assess pulmonary ventilation. The generator produces 81mKr from its parent rubidium-81 (81Rb).
Radiolabeled sodium chromate (51Cr) binds to red blood cells, tagging them for survival studies. 51Cr emits gamma radiation, allowing detection and quantification of RBC mass and survival via scintillation counting or imaging.
Intravenous infusion of krypton-81m gas in oxygen, typically 400-800 MBq (10-20 mCi) per study, administered via generator elution with a flow rate of 500-1000 mL/min. Adult dose per lung ventilation study: 100-400 MBq (2.7-10.8 mCi) inhaled in a single breath or continuous breathing for 1-2 minutes.
Intravenous injection, 5-30 microcuries (0.185-1.11 MBq) as a single dose.
None Documented
None Documented
Physical half-life of krypton-81m: 13.1 seconds; biological half-life is negligible as it is inert gas eliminated via exhalation.
The biological half-life is approximately 27–30 days. Clinically, gradual clearance from blood and tissues occurs over weeks to months.
Renal: ~100% (krypton-81m is exhaled and decay products are excreted renally; as a gas, the primary elimination is via exhalation, with the decay product rubidium-81 cleared renally).
Primarily renal. Approximately 90% of absorbed dose is excreted in urine within 48 hours. Fecal excretion accounts for less than 5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical